196 related articles for article (PubMed ID: 22932760)
1. Urinary BTA: indicator of bladder cancer or of hematuria.
Miyake M; Goodison S; Rizwani W; Ross S; Bart Grossman H; Rosser CJ
World J Urol; 2012 Dec; 30(6):869-73. PubMed ID: 22932760
[TBL] [Abstract][Full Text] [Related]
2. The BTA stat test is nonspecific for hematuria: an experimental hematuria model.
Oge O; Kozaci D; Gemalmaz H
J Urol; 2002 Mar; 167(3):1318-9; discussion 1319-20. PubMed ID: 11832722
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection.
Urquidi V; Goodison S; Kim J; Chang M; Dai Y; Rosser CJ
Urology; 2012 May; 79(5):1185.e1-6. PubMed ID: 22386755
[TBL] [Abstract][Full Text] [Related]
4. BTA stat and BTA TRAK: A comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder.
Irani J; Desgrandchamps F; Millet C; Toubert ME; Bon D; Aubert J; Le Duc A
Eur Urol; 1999 Feb; 35(2):89-92. PubMed ID: 9933800
[TBL] [Abstract][Full Text] [Related]
5. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
6. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?
Mahnert B; Tauber S; Kriegmair M; Nagel D; Holdenrieder S; Hofmann K; Reiter W; Schmeller N; Stieber P
Clin Chem Lab Med; 2003 Jan; 41(1):104-10. PubMed ID: 12636058
[TBL] [Abstract][Full Text] [Related]
7. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder.
Babjuk M; Kostírová M; Mudra K; Pecher S; Smolová H; Pecen L; Ibrahim Z; Dvorácek J; Jarolím L; Novák J; Zima T
Eur Urol; 2002 Jan; 41(1):34-9. PubMed ID: 11999463
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the BTA tests for the detection of bilharzial related bladder cancer: the Cairo experience.
Khaled HM; Abdel-Salam I; Abdel-Gawad M; Metwally A; El-Demerdash S; El-Didi M; Morsi A; Ishak L
Eur Urol; 2001 Jan; 39(1):91-4. PubMed ID: 11173945
[TBL] [Abstract][Full Text] [Related]
9. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer.
Thomas L; Leyh H; Marberger M; Bombardieri E; Bassi P; Pagano F; Pansadoro V; Sternberg CN; Boccon-Gibod L; Ravery V; Le Guludec D; Meulemans A; Conort P; Ishak L
Clin Chem; 1999 Apr; 45(4):472-7. PubMed ID: 10102906
[TBL] [Abstract][Full Text] [Related]
10. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
Raitanen MP;
World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
[TBL] [Abstract][Full Text] [Related]
11. The role of BTA stat in clinical practice.
Quek P; Chin CM; Lim PH
Ann Acad Med Singap; 2002 Mar; 31(2):212-6. PubMed ID: 11957560
[TBL] [Abstract][Full Text] [Related]
12. CCL18 in a multiplex urine-based assay for the detection of bladder cancer.
Urquidi V; Kim J; Chang M; Dai Y; Rosser CJ; Goodison S
PLoS One; 2012; 7(5):e37797. PubMed ID: 22629457
[TBL] [Abstract][Full Text] [Related]
13. Specificity of human complement factor H-related protein test (Bard BTA stat Test).
Raitanen MP; Tammela TL
Scand J Urol Nephrol; 1999 Aug; 33(4):234-6. PubMed ID: 10515085
[TBL] [Abstract][Full Text] [Related]
14. Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder.
Serretta V; Pomara G; Rizzo I; Esposito E
Eur Urol; 2000 Oct; 38(4):419-25. PubMed ID: 11025380
[TBL] [Abstract][Full Text] [Related]
15. Human complement factor H related protein test for monitoring bladder cancer.
Raitanen MP; Marttila T; Nurmi M; Ala-Opas M; Nieminen P; Aine R; Tammela TL;
J Urol; 2001 Feb; 165(2):374-7. PubMed ID: 11176376
[TBL] [Abstract][Full Text] [Related]
16. Effect of intravesical instillations on the human complement factor H related protein (BTA stat) test.
Raitanen MP; Hellström P; Marttila T; Korhonen H; Talja M; Ervasti J; Tammela TL;
Eur Urol; 2001 Oct; 40(4):422-6. PubMed ID: 11713397
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer.
Abd El Gawad IA; Moussa HS; Nasr MI; El Gemae EH; Masooud AM; Ibrahim IK; El Hifnawy NM
J Egypt Natl Canc Inst; 2005 Sep; 17(3):193-202. PubMed ID: 16799657
[TBL] [Abstract][Full Text] [Related]
18. BTA-TRAK combined with urinary cytology is a reliable urinary indicator of recurrent transitional cell carcinoma (TCC) of the bladder.
Mattioli S; Seregni E; Caperna L; Botti C; Savelli G; Bombardieri E
Int J Biol Markers; 2000; 15(3):219-25. PubMed ID: 11012097
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Bard Trak test with voided urine cytology in the diagnosis and follow-up of bladder tumors.
Chautard D; Daver A; Bocquillon V; Verriele V; Colls P; Bertrand G; Soret JY
Eur Urol; 2000 Dec; 38(6):686-90. PubMed ID: 11111185
[TBL] [Abstract][Full Text] [Related]
20. The role of the bladder tumour antigen test in the management of gross haematuria.
Chong TW; Cheng C
Singapore Med J; 1999 Sep; 40(9):578-80. PubMed ID: 10628246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
